Enterprise Therapeutics: Vital serviceEpidarex Capital-backed respiratory disease start-up Enterprise Therapeutics has named biotech entrepreneur John Ford as its new CEO. Ford previously co-founded Xention, Ario Pharma, and Metrion Biosciences. more ➔
Confo Therapeutics: Time for changeConfo Therapeutics wants to metamorphose from a tech company to a drug discovery company, and it has hired Cedric Ververken to guide the transition. more ➔
Arquer Diagnostics: New head for DxDiagnostics company Arquer Diagnostics Ltd (Sunderland, UK) has appointed Nadia Whittley as CEO, replacing Ian Campbell with immediate effect. Whittley will be responsible for launching the company’s … more ➔
Novo Nordisk: Passing the batonLars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development at Novo Nordisk, will take over the helm of the Danish diabetes major. He takes over from long-time CEO … more ➔
Acesion Pharma: New head of financeDanish biotech Acesion Pharma has hired Jakob Dynnes Hansen as its Chief Financial Officer. He joins from Evolva, a Swiss biotech company, where he has been CFO since 2007. more ➔
PharmaMar: Pushing the bordersPharmaMar is driving the expansion of its US operations. To this end, the company has appointed Pascal Besman to the newly created role of Chief Operation Officer of the marine-derived oncology drug … more ➔
BIA: Three new faces on the boardThe BIA has added three new members to the Board of Directors. Calchan CEO Brenda Reynolds (pictured), Immunocore Chief Business Officer Eva-Lotta Allan and Polar Capital’s Partner – Healthcare Dan Mahony … more ➔
Ayoxxa: Bridging the gapCologne-based biotech Ayoxxa Biosystems GmbH announces that Rodney Turner has assumed duties as the interim CEO. Prior CEO Andreas Schmidt has stepped down. more ➔
Merus: Changes in managementDutch immuno-oncology company Merus has appointed John Crowley its Chief Financial Officer. Former CFO Shelley Margetson has been elevated to Chief Operating Officer. more ➔
TxCell: Cell engineering virtuosoFrench cellular immunotherapy company TxCell has hired ex-Novartis Lab Head Li Zhou to lead its CAR-Treg programmes. Zhou was appointed Vice President Cell Engineering in October. more ➔
